Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T — Stella

Home/Recurrent Diffuse Large B-Cell Lymphoma/Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Diffuse Large B-Cell Lymphoma trials

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Key details

Phase

Safety & dosing

Sponsor

University of Washington

Collaborators

Regeneron Pharmaceuticals

Enrollment target

~27 participants

Started

September 2025

Primary completion

April 2028

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.